$AKBA News

Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...

Akebia Therapeutics (NASDAQ:AKBA) Slides 24.6% Despite Q2 Earnings Beat

Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics Q2 Earnings Call Highlights

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Akebia Therapeutics Initiates Phase 2 Basket Trial To Evaluate Safety, Efficacy, And Pharmacokinetics Of Ebribafusp For Treatment Of Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia: Vafseo Gains Traction, But It's Still A Show-Me Story (Rating Downgrade)

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)